Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,514.37 65.12 0.40%
S&P 500 1,879.55 7.66 0.41%
NASDAQ 4,161.46 39.91 0.97%
Ticker Volume Price Price Delta
STOXX 50 3,189.63 -10.06 -0.31%
FTSE 100 6,675.69 -6.07 -0.09%
DAX 9,581.19 -18.90 -0.20%
Ticker Volume Price Price Delta
NIKKEI 14,546.27 157.50 1.09%
TOPIX 1,173.81 11.31 0.97%
HANG SENG 22,509.64 -221.04 -0.97%

BAYER GETS CLEARANCE TO BUY TEVA ANIMAL HEALTH BUSINESS (ENG)


(The following press release from Bayer was received by e-mail. It was not confirmed by the sender.)

News-Release

Not intended for U.S. media Bayer HealthCare completes acquisition of Teva’s U.S. animal health business New product lines strengthen Bayer’s animal health business in the U.S.

Leverkusen, January 4, 2013 - Bayer HealthCare announced today that it has received the necessary regulatory approval from the Federal Trade Commission to complete the acquisition of the U.S.-based animal health business of Teva Pharmaceutical Industries Ltd. (NYSE: TEVA). As announced in September 2012, Bayer will pay up to 145 million USD which includes an upfront payment of 60 million USD plus a total of 85 million USD in milestone payments, which are linked to the successful and timely achievement of manufacturing and sales targets. The transaction includes a manufacturing site in St. Joseph, Missouri and around 300 employees.

"This acquisition fits nicely with our strategic goals. It allows us to strengthen and broaden our range of animal care solutions in the US market," said Dr. Joerg Reinhardt, Chief Executive Officer, Bayer HealthCare.

The new portfolio will include a strong anti-infectives franchise and will enable Bayer to be present in all major therapeutic areas. The companion animal products features a full line of dermatology products sold under the DVM Pharmaceutical brand, including such products as Malaseb, HyLyt, Relief and others. Further companion animal products include a broad line of nutraceuticals encompassing joint and gastro-intestinal products including the Synovi brands. Food animal products acquired from Teva include a wide range of anti-infectives in addition to parasiticides, anti-inflammatory brands and reproductive hormones.

About Bayer HealthCare The Bayer Group is a global enterprise with core competencies in the fields of health care, agriculture and high-tech materials. Bayer HealthCare, a subgroup of Bayer AG with annual sales of EUR 17.2 billion (2011), is one of the world’s leading, innovative companies in the healthcare and medical products industry and is based in Leverkusen, Germany. The company combines the global activities of the Animal Health, Consumer Care, Medical Care and Pharmaceuticals divisions. Bayer HealthCare’s aim is to discover, develop, manufacture and market products that will improve human and animal health worldwide. Bayer HealthCare has a global workforce of 55,700 employees (Dec 31, 2011) and is represented in more than 100 countries. More information at http://www.healthcare.bayer.com.

Our online press service is just a click away: http://press.healthcare.bayer.com

Find more information at http://www.animalhealth.bayerhealthcare.com Follow us on Facebook: http://www.facebook.com/healthcare.bayer

Forward-Looking Statements This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer Group or subgroup management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer’s public reports which are available on the Bayer website at http://www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.

Contact: Bayer Animal Health GmbH Kathrin Statz, Tel. +49 2173 38-4019 E-Mail: mailto:kathrin.statz@bayer.com

This press release is available here: http://www.baynews.bayer.de/baynews/baynews.nsf/id/2013-0003-e

Yours BayNews Editorial Team

Bayer AG Communications Building W11 51368 Leverkusen, Germany

---------------------------------------------------

Further news releases you can find here: http://www.press.bayer.com

To ensure receipt, please add pressrelease@bayer-newsletter.de to your address book or list of trusted senders.

---------------------------------------------------

© Bayer AG, 51368 Leverkusen, Germany

All rights reserved. The entire contents, including images, graphics, animations etc., of this e-mail and the server http://www.press.bayer.com are copyrighted.

Board of Management: Marijn Dekkers, Chairman of the Board | Werner Baumann, Wolfgang Plischke, Richard Pott Chairman of the Supervisory Board: Werner Wenning Registered Office: Leverkusen | Local Court Cologne, HRB 48248

Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement